SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are experiencing strong momentum driven by robust first-quarter earnings that surpassed revenue and profitability estimates, fueling a wave of analyst price target upgrades. The community is actively discussing the company's platform growth, its milestone of exceeding 100 million active households, and continued speculation regarding potential acquisition interest from major media companies.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as a key player in the decentralized AI sector, driven by a structural narrative that positioning it as a permissionless, global alternative to the increasingly restricted and centralized AI models offered by big tech. The community is actively debating the network's long-term utility versus its risks, while many are focused on the integration of subnets and the broader potential of decentralizing AI infrastructure.

Tidal Trust II - Defiance Daily Target 2X Short ASTS ETF

ASTN is gaining attention as traders utilize the leveraged inverse ETF to bet against the volatility and high-profile hype surrounding ASTS. Community sentiment is deeply polarized, with participants actively debating whether to capitalize on potential price pullbacks or remain long in a stock frequently cited as a meme-driven opportunity.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh strong Phase 3 clinical data for its gene-editing HAE therapy against a recent equity offering, which has sparked intense debate over dilution and potential short-squeeze dynamics. The community remains focused on the company's long-term commercial potential, institutional accumulation, and whether the recent capital raise serves as a strategic runway or a near-term headwind.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is drawing attention as a potential M&A target amid ongoing market speculation, with investors closely watching institutional activity and the company's aggressive pipeline expansion. Community sentiment remains focused on the drug's long-term commercial potential and the likelihood of a high-premium buyout as institutional investors weigh growth versus profitability.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery shareholders are preparing to vote on the proposed $110 billion merger with Paramount Skydance, a deal that has received unanimous board support despite significant pushback from Hollywood creators and industry figures concerned about media consolidation. The community is closely watching the vote for clarity on the merger's path forward, as well as the controversy surrounding the CEO's substantial compensation package and ongoing regulatory scrutiny.

Bitwise Hyperliquid ETF - Bitwise Hyperliquid ETF

Bitwise Hyperliquid ETF

The Bitwise Hyperliquid ETF is gaining significant traction as investors view it as a primary vehicle for gaining direct exposure to the Hyperliquid ecosystem and its growth potential. The community is actively debating the product's long-term utility and institutional interest, frequently citing its role in facilitating access to emerging asset classes and pre-IPO trading opportunities.

PolySwarm

PolySwarm ($NCT) is capturing community attention due to its extremely low float and persistent chatter about its potential for momentum-driven price action in the cybersecurity sector. Investors are closely monitoring the token's technical consolidation and tight price action, with many discussing its long-term utility while actively looking for signs of a significant breakout.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is facing heightened scrutiny as it caps withdrawals on a flagship private credit fund following a surge in redemption requests, fueling broader market concerns about liquidity and loan quality in the sector. Investors are actively discussing the potential systemic risks of these private credit constraints, especially as the firm's stock reacts to both negative valuation write-downs and its ongoing expansion into tokenized assets and crypto ETFs.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened engagement as investors react to Cathie Wood's aggressive portfolio rebalancing, specifically her significant accumulation of SpaceX shares and shifts away from legacy biotech and semiconductor holdings. Community debate remains polarized, with many users criticizing the fund's historical underperformance and high fees while others highlight its structural role in providing exposure to speculative, high-volatility innovation themes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Amgen Inc. (AMGN) A Good Stock To Buy Now?

Is Amgen Inc. (AMGN) A Good Stock To Buy Now...

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS PR Newswire THOUSAND OAKS, Calif., June 7, 2026 VESALIUS-CV...

Amgen: A Biotech Giant's Path to Recovery and Growth

Explore the exciting world of Amgen (NASDAQ: AMGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Apr...

Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 4, 2026 THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the...

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge

Equity

Neutral Sentiment

Track AMGN stock price, charts, news and real-time market activity on Stocktwits. Join the AMGN message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AMGEN Inc stock.

AMGNAMGEN Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMGN News